Sudo Biosciences
Carmel, United States · Biopharma, Biotechnology, Biotechnology Research
Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 inhibitors to transform the treatment of immune-mediated diseases. Its pipeline includes a potential first- and best-in-class, once-daily oral, brain-penetrant candidate for multiple sclerosis and other neuroinflammatory conditions, as well as a topical candidate for dermatologic diseases. Based in Carme
Key facts
- Headquarters
- Carmel, United States
- Employees
- 24
- Industries
- Biopharma, Biotechnology, Biotechnology Research
- Status
- Private
- Website
- sudobio.com
- Company page
Recent activity at Sudo Biosciences
- : Sudo Biosciences Appoints Paul Bavier as Chief Legal Officer
- : Sudo Biosciences Launches Phase 1 Trial for SUDO-550, a Novel TYK2 Inhibitor Targeting Neuroinflammatory Diseases.
- : Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
- : Sudo Biosciences
- : Sudo Biosciences Raises $116M Series B Financing To Advance Potential Best-In-Class Tyk2 Therapeutics Programs Into The Clinic
Sudo Biosciences funding history
| Date | Round | Amount |
|---|---|---|
| Feb 2024 | Series B | $147.0M |
| Dec 2023 | Venture | $53.3M |
| Dec 2023 | Series B | $116.0M |
Leadership
- Paul Bavier, Chief Legal Officer
- Ian Mills, Chief Medical Officer
- Scott Byrd, Chief Executive Officer
Verified email and direct lines for Sudo Biosciences’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Companies similar to Sudo Biosciences
- YS Biopharma · Biopharma, Biotechnology, Biotechnology Research, Health Care, Therapeutics
- Tempest Therapeutics · Biopharma, Biotechnology, Health Care, Therapeutics
- BerGenBio ASA · Biopharma, Biotechnology, Health Care, Therapeutics
- Newron Pharmaceuticals S.p.A. & EA Pharma Ltd · Biopharma, Biotechnology, Health Care, Therapeutics
- OnCusp Therapeutics · Biopharma, Biotechnology, Health Care, Therapeutics
About Sudo Biosciences: questions and answers
What does Sudo Biosciences do?
Sudo Biosciences is a clinical-stage biopharmaceutical company developing next-generation TYK2 inhibitors to transform the treatment of immune-mediated diseases. Its pipeline includes a potential first- and best-in-class, once-daily oral, brain-penetrant candidate for multiple sclerosis and other neuroinflammatory conditions, as well as a topical candidate for dermatologic diseases. Based in Carme
Where is Sudo Biosciences headquartered?
Sudo Biosciences is headquartered in Carmel, United States.
How many employees does Sudo Biosciences have?
Sudo Biosciences has about 24 employees.
Has Sudo Biosciences raised funding?
Yes. Fundz has recorded 3 funding events for Sudo Biosciences. The most recent, Series B of $147.0M, was in Feb 2024.
Who leads Sudo Biosciences?
Scott Byrd is a Chief Executive Officer at Sudo Biosciences.
What is the latest news on Sudo Biosciences?
On Dec 04, 2025, Sudo Biosciences Appoints Paul Bavier as Chief Legal Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy